You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 2.2% | 2.3% |
Div Cover | 1.3 | 2.6 |
Op Mrgn | 17.9% | 30.8% |
ROCE | 60.1% |
Latest | Forecast | |
---|---|---|
P/E | 35.1 | 0.0 |
PEG | 0.4 | 0.2 |
Price / Revenue | 4.6 | 3.2 |
Price / Book value | 5.3 |
Latest | Forecast | |
---|---|---|
Revenue | 3.3% | 0.9% |
PBT | 175.8% | n/a |
EPS | 81.1% | -39.0% |
DPS | 0.0% | -36.9% |
Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 24,384.00 | 1,548.00 | $1.03 | 97.9 | -2.5 | -39% | $2.80 | 2.8% |
2020-12-31 | 26,617.00 | 3,916.00 | $2.44 | 41.0 | 0.3 | 137% | $2.80 | 2.8% |
2021-12-31 | 37,417.00 | -265.00 | $0.08 | 1,467.0 | -15.2 | -97% | $2.87 | 2.4% |
2022-12-31 | 44,351.00 | 2,501.00 | $2.12 | 64.0 | 0.0 | 2,550% | $2.90 | 2.1% |
2023-12-31 | 45,811.00 | 6,899.00 | $3.84 | 35.2 | 0.4 | 81% | $2.90 | 2.1% |
AstraZeneca gets FDA approval for Ultomiris treatment Sharecast News | 25 Mar |
---|---|
AstraZeneca to buy US-listed Fusion Pharma for $2bn Sharecast News | 19 Mar |
AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn Sharecast News | 14 Mar |
Ultomiris approved in the US for NMOSD | 25-Mar-24 07:01 |
---|---|
AstraZeneca to acquire Fusion | 19-Mar-24 07:01 |
AstraZeneca to acquire Amolyt | 14-Mar-24 07:01 |
Director/PDMR Shareholding | 12-Mar-24 11:02 |
Notice of AGM | 07-Mar-24 11:00 |